Vasopressor Pharmacology for ICU Nurses
How do vasopressors change blood pressure and perfusion?
Vasoactive drugs change vascular tone, cardiac contraction or both. Norepinephrine, epinephrine, phenylephrine and vasopressin differ in receptor activity and hemodynamic effects. Dobutamine and milrinone primarily support contraction while also promoting vasodilation. Start with the patient’s pressure, flow and perfusion problem, then connect the drug’s mechanism to the response.
Key takeaways
- An improved MAP does not prove cardiac output or tissue perfusion improved.
- Phenylephrine and vasopressin increase vascular tone through different receptors.
- Dobutamine and milrinone support contractility through different entry points into cyclic AMP signaling.
How do you connect a vasoactive drug to the patient’s problem?
Separate vascular tone from forward flow. A vasodilated patient and a patient with low cardiac output require different reasoning even if their arterial pressures look similar. Compare the pressure with the rhythm, available cardiac output data and bedside evidence of perfusion.
A drug’s expected effects guide reassessment. Increasing vascular resistance raises the load against which the left ventricle ejects blood. Supporting contraction carries different tradeoffs, including changes in heart rate and myocardial oxygen demand.
How do common vasopressors differ?
Norepinephrine has strong alpha activity with beta-1 effects. Epinephrine acts at alpha and beta receptors. Phenylephrine primarily activates alpha-1 receptors. Vasopressin activates V1a receptors on vascular smooth muscle. These differences help explain why a similar MAP response does not imply identical effects on heart rate or flow.
Sachi follows the receptor into intracellular signaling, then returns to the patient. Learn the pathway as a causal explanation rather than a list of abbreviations. Dose, patient physiology and the treatment context all influence the observed response.
Where do dobutamine and milrinone fit?
Dobutamine acts mainly through beta-1 signaling. Milrinone inhibits phosphodiesterase 3, slowing cyclic AMP breakdown. Both support cardiac contraction and have vasodilatory effects, so an improvement in contraction does not guarantee arterial pressure rises.
For a clinical interview, explain the hemodynamic goal, receptor or enzyme, expected effect and a meaningful adverse effect. For current sepsis treatment recommendations, use the updated Surviving Sepsis Campaign guidance alongside the mechanism lesson.
